SCHEMBL6068841

SCHEMBL6068841

Cc1oc(-c2ccc(C(F)(F)F)cc2)nc1-c1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.73
KIF11 P52732 1/20 0.54
IKBKB O14920 1/20 0.44
LMNA P02545 2/20 0.43
THRB P10828 1/20 0.43
PPARD Q03181 2/20 0.42
PPARG P37231 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
MAPK1 P28482 1/20 0.42
MAP2K4 P45985 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
MAPKAPK3 Q16644 1/20 0.42
MAPK6 Q16659 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6069114 0.90 PTPN1 (0.64) PTPN1KIF11IKBKBLMNACYP1A2
SCHEMBL6069329 0.87 PTPN1 (0.63) PTPN1KIF11IKBKBPPARDPPARG
SCHEMBL6069273 0.84 PTPN1 (1.00) PTPN1KIF11IKBKBLMNATHRB
SCHEMBL6069089 0.84 PTPN1 (0.70) PTPN1IKBKBLMNATHRBPPARD
SCHEMBL6069281 0.83 PTPN1 (0.67) PTPN1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6069045 0.82 PTPN1 (0.61) PTPN1IKBKBLMNATHRBPPARD
SCHEMBL6069378 0.82 PTPN1 (0.61) PTPN1IKBKBLMNATHRBPPARD
SCHEMBL6069381 0.82 PTPN1 (0.61) PTPN1IKBKBLMNATHRBPPARD
SCHEMBL6069138 0.82 PTPN1 (0.61) PTPN1IKBKBLMNATHRBPPARD
SCHEMBL27565947 0.79 PTPN1 (0.55) PTPN1LMNACYP1A2CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147755-A1 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2004-07-29 US claimed
US-6699896-B1 METABOLIC DISORDERS, ANTIDIABETIC AGENTS; OBESITY WYETH 2004-03-02 US claimed
EP-1077958-A1 OXAZOLE-ARYL-CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP claimed
WO-1999058511-A1 OXAZOLE-ARYL-CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO claimed
US-7141672-B2 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2006-11-28 US disclosed
US-20040147755-A1 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2004-07-29 US disclosed
US-6699896-B1 METABOLIC DISORDERS, ANTIDIABETIC AGENTS; OBESITY WYETH 2004-03-02 US disclosed
EP-1077966-B1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-11-20 EP disclosed
US-6310081-B1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AMERICAN HOME PRODUCTS CORPORATION 2001-10-30 US disclosed
US-6221902-B1 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS AMERICAN HOME PRODUCTS CORPORATION 2001-04-24 US disclosed
EP-1077966-A1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
EP-1077958-A1 OXAZOLE-ARYL-CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
WO-1999058520-A1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed
WO-1999058511-A1 OXAZOLE-ARYL-CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147755-A1 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, GCKR PTPN1 870/4885KIF11 3722/4885IKBKB 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.